The first results of a key study on vaccine responses in chronic lymphocytic leukaemia patients has been published in preprint in Lancet.
"In summary, this study has shed some light on those most at risk in the CLL population and gives others cause for hope. However, we would advise that you interpret results with caution and remain vigilant against the risk of catching, as the limitations of the study prevented the researchers from being able to give further advice to patients."
In this review blog our Patient Advocacy Manager, Charlotte, outlines the first reaction to the news and what the takeaway messages are for patients and their loved ones. leukaemiacare.org.uk/suppor...
Pre- print scientific paper papers.ssrn.com/sol3/papers...
Thank you to everyone who was able to give their blood and participate in this study. As more information comes available from the study we will have a clearer picture. But what we now know is helpful to ensure we maintain vigilance.
Nick
